Prenetics Reports Strong Q1 2026 Results & IM8 Growth

New York, N.Y. - Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, announced its preliminary unaudited financial results for the first quarter ended March 31, 2026. The company reported significant momentum in its premium health and longevity brand, IM8, which experienced nearly 6x year-over-year revenue growth.

The company highlighted a strategic shift toward quarterly subscription plans, which has resulted in a substantial increase in average order value. As a result of this strong operational performance and growing demand across 43 international markets, Prenetics has raised its full-year 2026 IM8 revenue guidance to a range of $190 million to $210 million.

Financial Highlights

• Total Q1 2026 revenue reached $36.0 million.
• IM8 revenue contributed $33.8 million, a 23.1% increase from Q4 2025.
• Gross profit for the quarter was $23.3 million.
• Adjusted EBITDA loss was reported at $5.6 million.
• Cash and cash equivalents stood at $56.0 million as of March 31, 2026, with no debt.

Operational Updates

• IM8 monthly revenue for April 2026 hit approximately $14.0 million, with projections of $15.5 million for May 2026.
• Total servings delivered by IM8 grew by 28% quarter-over-quarter to 8.8 million+.
• The company continues to execute a $40 million share buyback program, having repurchased approximately $19 million in shares to date.
• Brian J. Rosin has been appointed as the new Chief Financial Officer of IM8 to support further global expansion.

Looking ahead, Prenetics plans to diversify its product portfolio in Q4 2026 by launching new SKUs in the hydration, creatine, and kids' gummy categories, leveraging the brand's established global distribution network and scientific advisory board.